

ANTEO ENTERS INTO FIRST MTA FOR BATTERY DEVELOPMENT

ASX Release

6 August 2018

HIGHLIGHT

- Anteo Diagnostics has entered into its first Materials Transfer Agreement (“**MTA**”) with a major Asian/ Global Manufacturer of Battery Materials

Anteo Diagnostics Ltd (“**Anteo**” or the “**Company**”) is pleased to announce it has executed its first MTA with a major Asian/ Global Battery Materials and Component Manufacturer. The agreement follows the work that Anteo has been conducting to characterize and validate the potential for AnteoCoat™ in increasing Silicon content and improving the performance and manufacturability of Lithium-ion battery anodes.

The MTA sets out the pathway for exchanging materials between the parties to further assess the potential of AnteoCoat™ to improve battery anode performance using their proprietary materials. The first steps under the agreement are to define the feasibility study parameters to determine the potential work which will be conducted by both parties with information on outcomes exchanged under confidentiality.

Mr. Christopher Parker, Anteo Diagnostics CEO, said “This is a great step and an endorsement of the work that Anteo has been conducting to internally and externally characterize and validate the potential of AnteoCoat™. Our objectives are to give a significant energy capacity improvement to Lithium-ion battery anodes in the future coupled with ease of manufacture.”

Shareholders are reminded that Anteo Diagnostics will be hosting a series of Shareholder Information sessions in Brisbane, Sydney and Melbourne over the 7, 8 and 9 August respectively. These sessions will detail the Company’s strategy in relation to battery commercialization. In addition, an update will be provided on progress that has been made in the Point of Care testing project. For details please refer to previous release on 23 July 2018 and available on the Company’s web site.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX)

Anteo Group is a surface chemical company with Intellectual Property (“**IP**”) in its core technology product groups AnteoCoat, AnteoBind and AnteoRelease. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Anteo’s customers operate in the life sciences, diagnostics, energy and medical devices markets.

For more information, please visit www.anteotech.com